CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
| Project Number | PC0147-000 |
|---|---|
| Brand Name | Opdivo |
| Generic Name | Nivolumab |
| Strength | 40 mg & 100 mg |
| Tumour Type | Skin & Melanoma |
| Indication | Melanoma Adjuvant Therapy |
| Funding Request | For the adjuvant treatment of adult patients after complete resection of melanoma with regional lymph node involvement, in transit metastases/satellites without metastatic nodes, or distant metastases |
| Review Status | Notification to Implement Issued |
| Pre Noc Submission | Yes |
| NOC Date | November 15, 2018 |
| Manufacturer | Bristol-Myers Squibb Canada |
| Sponsor | Bristol-Myers Squibb Canada |
| Submission Date | August 27, 2018 |
| Submission Deemed Complete | September 11, 2018 |
| Submission Type | Initial |
| Prioritization Requested | Requested and Granted |
| Stakeholder Input Deadline ‡ | September 11, 2018 |
| Check-point meeting | October 17, 2018 |
| pERC Meeting | December 13, 2018 |
| Initial Recommendation Issued | January 4, 2019 |
| Feedback Deadline ‡ | January 18, 2019 |
| pERC Reconsideration Meeting | February 21, 2019 |
| Final Recommendation Issued | March 7, 2019 |
| Notification to Implement Issued | March 22, 2019 |
| Therapeutic Area | Melanoma Adjuvant Therapy |
| Recommendation Type | Reimburse with clinical criteria and/or conditions |
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
